Tempus AI, Inc. $TEM Shares Bought by Virtu Financial LLC

Virtu Financial LLC lifted its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 384.6% during the 4th quarter, HoldingsChannel reports. The fund owned 54,797 shares of the company’s stock after acquiring an additional 43,490 shares during the period. Virtu Financial LLC’s holdings in Tempus AI were worth $3,236,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of TEM. Vanguard Group Inc. boosted its position in shares of Tempus AI by 22.1% in the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after buying an additional 1,706,837 shares during the period. Krane Funds Advisors LLC grew its stake in shares of Tempus AI by 218.2% in the third quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after buying an additional 19,358 shares in the last quarter. Aberdeen Group plc raised its holdings in shares of Tempus AI by 64.2% during the 4th quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock valued at $15,530,000 after buying an additional 102,878 shares during the period. Pictet Asset Management Holding SA raised its holdings in shares of Tempus AI by 291.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after buying an additional 36,096 shares during the period. Finally, Bogart Wealth LLC raised its holdings in shares of Tempus AI by 365,087.5% during the 4th quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock valued at $3,450,000 after buying an additional 58,414 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Eric P. Lefkofsky sold 166,250 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $46.70, for a total transaction of $7,763,875.00. Following the completion of the transaction, the chief executive officer directly owned 8,808,533 shares in the company, valued at approximately $411,358,491.10. This represents a 1.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Polovin sold 8,703 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $383,541.21. Following the sale, the executive vice president directly owned 128,215 shares of the company’s stock, valued at $5,650,435.05. The trade was a 6.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 558,557 shares of company stock worth $26,611,939 over the last quarter. Corporate insiders own 24.26% of the company’s stock.

Tempus AI Stock Up 4.2%

Shares of Tempus AI stock opened at $50.84 on Friday. Tempus AI, Inc. has a 1-year low of $41.73 and a 1-year high of $104.32. The company has a market capitalization of $9.13 billion, a PE ratio of -29.56 and a beta of 3.62. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. The business has a 50-day moving average of $49.59 and a 200-day moving average of $55.93.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.08. The business had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The company’s revenue was up 36.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. As a group, equities analysts forecast that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on TEM shares. JPMorgan Chase & Co. decreased their price target on Tempus AI from $80.00 to $60.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Guggenheim lowered their price objective on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, March 30th. BTIG Research reiterated a “buy” rating and set a $80.00 price objective on shares of Tempus AI in a research note on Monday, June 1st. Morgan Stanley reduced their target price on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Finally, HC Wainwright decreased their target price on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a research note on Monday, May 11th. Nine investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Tempus AI currently has a consensus rating of “Hold” and an average target price of $68.64.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.